<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03532711</url>
  </required_header>
  <id_info>
    <org_study_id>FUSCC-BiomarkerCRC</org_study_id>
    <nct_id>NCT03532711</nct_id>
  </id_info>
  <brief_title>Potential Predictive Biomarkers in Patients Undergoing First-line Chemotherapy for Metastatic Colorectal Cancer</brief_title>
  <official_title>A Study to Characterize and Evaluate Biomarkers of Chemotherapy in Patients With Metastatic Colorectal Cancer In The First-line Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemoresistance remains an obstacle in treating people with metastatic colorectal cancer
      (mCRC). Studying samples of blood and tumor tissue in the laboratory from patients with mCRC
      receiving chemotherapy may help doctors understand the effect of chemotherapy on biomarkers.
      It may also help doctors predict how patients will respond to treatment. In this study, we
      aimed to evaluate biomarkers in chemotherapy regimens for first-line chemotherapy for mCRC.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2012</start_date>
  <completion_date type="Actual">December 31, 2016</completion_date>
  <primary_completion_date type="Actual">June 30, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>2 months</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>6 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>6 months</time_frame>
    <description>progression free survival</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">264</enrollment>
  <condition>Metastatic Colorectal Cancer</condition>
  <condition>Chemotherapy Effect</condition>
  <condition>Biomarker</condition>
  <arm_group>
    <arm_group_label>Chemotherapy</arm_group_label>
    <description>FOLFOX/XELOX/FOLFIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fluorouracil</intervention_name>
    <description>chemotherapy treated patients</description>
    <arm_group_label>Chemotherapy</arm_group_label>
    <other_name>capecitabine</other_name>
    <other_name>irinotecan hydrochloride</other_name>
    <other_name>leucovorin calcium</other_name>
    <other_name>oxaliplatin</other_name>
    <other_name>laboratory biomarker analysis</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Histologically confirmed metastatic colorectal cancer
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria Histologically confirmed metastatic colorectal cancer Unresectable
        metastatic disease must be confirmed histologically if &gt; 2 years since primary diagnosis
        Measurable metastatic disease &gt; 1 cm by spiral CT scan or &gt; 2 cm by other methods Scheduled
        to receive first-line chemotherapy for metastatic disease Chemotherapy must include
        fluorouracil, capecitabine, irinotecan hydrochloride, or oxaliplatin Exclusion Criteria
        Inadequate or unusable tissue as the only tissue available Brain metastases or meningeal
        disease Contraindication to chemotherapy Pregnant or nursing Other severe pathology that is
        likely to worsen during therapy Dementia or severely impaired mental condition Geographical
        or psychological reasons that would preclude treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2018</study_first_submitted>
  <study_first_submitted_qc>May 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2018</study_first_posted>
  <last_update_submitted>May 20, 2018</last_update_submitted>
  <last_update_submitted_qc>May 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

